Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
3 min read
Decoding Casirivimab: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
31 October 2023
This article summarized the latest R&D progress of Casirivimab, the Mechanism of Action for Casirivimab, and the drug target R&D trends for Casirivimab.
Bio Sequence
3 min read
Toripalimab: FDA Greenlights First made-in-China PD-1 and Its Evolving Competitive Landscape
31 October 2023
According to the Patsnap Bio Sequence Database, the top 10 applicants for the toripalimab patent are as follows: Shanghai Junshi Biosciences with 52 applications, Cugene with 30 applications, and Guangzhou Zhiyi Biotech with 16 applications. For more applicants, please refer to the image below.
Drug Insights
4 min read
An In-depth Analysis of Cephradine's R&D Progress and Mechanism of Action on Drug Target
30 October 2023
This article summarized the latest R&D progress of Cephradine, the Mechanism of Action for Cephradine, and the drug target R&D trends for Cephradine.
Latest Hotspot
3 min read
CSPC Pharmaceutical Group's Claudin6/CD137 Dual Antibody NBL-028 has been approved for clinical trials, aimed at treating late-stage solid tumors
30 October 2023
Recently, CSPC Pharmaceutical announced that its independently developed bispecific antibody targeting Claudin6/CD137, NBL-028, has received approval from the National Medical Products Administration (NMPA) in China for clinical trial applications.
Drug Insights
4 min read
Cilnidipine: Detailed Review of its Transformative R&D Success
30 October 2023
This article summarized the latest R&D progress of Cilnidipine, the Mechanism of Action for Cilnidipine, and the drug target R&D trends for Cilnidipine.
Bio Sequence
2 min read
Biological Glossary | What is Consensus Sequence?
30 October 2023
In molecular biology and bioinformatics, a consensus sequence is a sequence of DNA, RNA, or protein that represents the most common or typical sequence found in a specific location within a population.
Drug Insights
4 min read
Benzydamine Hydrochloride Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
30 October 2023
This article summarized the latest R&D progress of Benzydamine Hydrochloride, the Mechanism of Action for Benzydamine Hydrochloride, and the drug target R&D trends for Benzydamine Hydrochloride.
Latest Hotspot
3 min read
Biogen's tau-targeted antisense oligonucleotide therapy shows positive clinical data in the treatment of Alzheimer's disease
30 October 2023
Recently, Biogen announced positive results from the Phase 1b trial of BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau protein for the treatment of mild Alzheimer's Disease (AD).
Drug Insights
4 min read
Unleashing the Power of Benazepril Hydrochloride: A Comprehensive Review on R&D Breakthroughs
30 October 2023
This article summarized the latest R&D progress of Benazepril Hydrochloride, the Mechanism of Action for Benazepril Hydrochloride, and the drug target R&D trends for Benazepril Hydrochloride.
Bio Sequence
2 min read
Biological Glossary | What is Coding Sequence (CDS)?
30 October 2023
A coding sequence (CDS) is a portion of a gene or an mRNA molecule that specifically codes for a protein.
Drug Insights
4 min read
A Comprehensive Review of Belantamab mafodotin's R&D Innovations and Drug Target Mechanism
30 October 2023
This article summarized the latest R&D progress of Belantamab mafodotin, the Mechanism of Action for Belantamab mafodotin, and the drug target R&D trends for Belantamab mafodotin.
Latest Hotspot
3 min read
Immatics TCR-T therapy IMA203 is granted RMAT designation by CBER for the treatment of multiple types of cancer
30 October 2023
Recently, Immatics announced that its T cell receptor T cell (TCR-T) therapy IMA203 under research has been granted the Regenerative Medicine Advanced Therapy (RMAT) designation by the Center for Biologics Evaluation and Research (CBER) of the U.S. FDA.